University of Michigan
Dr. Koschmann is a Pediatric Neuro-Oncologist in the Department of Pediatrics and a Principal Investigator of an independent translational Pediatric Neuro-Oncology laboratory. His work in the clinic and lab complement and drive each other, resulting in a clear goal to improve therapies for children with brain tumors. He has engaged in research and the clinical care of pediatric brain tumor patients at both Seattle Children’s Hospital and the University of Michigan’s Mott Children’s Hospital. The Koschmann laboratory is exploring the molecular mechanisms by which recurrent mutations in pediatric high-grade glioma (HGG), including glioblastoma (GBM), anaplastic astrocytoma (AA) and diffuse intrinsic pontine glioma (DIPG) promotes tumor formation and affect treatment response.
Dr. Koschmann has applied this precision medicine approach in translational and clinical work in Pediatric Neuro-Oncology. Along with researchers and colleagues from multiple clinical divisions at the University of Michigan and other institutions, he developed and co-facilitate the UM CNS Precision Medicine conference. In this multi-disciplinary and multi-institutional conference, molecular results are incorporated from pediatric brain tumor patients (paired tumor/germline sequencing results and pre-clinical cell culture treatment studies) into their treatment. Dr. Koschmann has established new algorithms and are in the process of developing multiple clinical trials incorporating the use of molecularly targeted therapy for pediatric patients with brain tumors. He will serve as PI for these trials and their biologic correlative research.
Regional Response to ONC201 in Pediatric High-Grade Glioma
Pediatric High-grade glioma with H3K27M mutation (H3K27M-pHGG) carries an average overall survival of 1-2 years, and new targeted therapies are needed urgently. ONC201 is a dopamine receptor (DRD2) antagonist that is effective against H3K27M-pHGGs in pre-clinical and anecdotal clinical (case repo
Comparison of fusion calling platforms in pediatric DIPG and high‐grade glioma
DIPGs are especially lethal and confer a despairingly short 11-month median survival due to their aggressive phenotype and lack of therapeutic options. Molecular characterization of pediatric brain tumors is stimulating the development and testing of targeted therapies for precision medicine. How
High-grade glioma/astrocytoma (WHO grade III/IV)
High-grade Gliomas (HGG) in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric specific HGG preclinical models. These models are needed to help test the effective
Brainstem glioma- Diffuse intrinsic pontine glioma
A presumptive diagnosis of DIPG based on classic imaging features, in the absence of a histologic diagnosis, has been routinely employed. Increasingly however, histologic confirmation is obtained for both entry into research studies and molecular characterization of the tumor.[